ACET / Adicet Bio, Inc. - تصريحات هيئة الأوراق المالية والبورصات، التقرير السنوي، بيان الوكيل

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in auto

Adicet Bio Reports Second Quarter 2025 Financial Results and Provides Business Updates Actively enrolling patients with lupus nephritis (LN), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc) in Phase 1 clinical trial of ADI-001 in autoimmune diseases On track to report preliminary clinical data for ADI-001 in 2H/2025 Enrollment now open for patients with idiopathic inflammatory myop

LICENSE AND COLLABORATION AGREEMENT

Exhibit 10.1 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LICENSE AND COLLABORATION AGREEMENT This LICENSE AND COLLABORATION AGREEMENT (this “Agreement”) is entered into as of May 16th, 2023 (the “Effective Dat

NON-EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.2 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. NON-EXCLUSIVE LICENSE AGREEMENT THIS NON-EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is made and entered into as of July 9, 2024 (the “Effective Date

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N

As filed with the Securities and Exchange Commission on July 25, 2025

As filed with the Securities and Exchange Commission on July 25, 2025 Registration No.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc.

FORM 8-K Item 2.05 Costs Associated with Exit or Disposal Activities. Item 8.01 Other Events. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio, Inc. Pipeline Chart, as of July 23, 2025.

Exhibit 99.1

FORM 8-K Item 5.07 Submission of Matters to a Vote of Security Holders.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2

Adicet Bio Reports First Quarter 2025 Financial Results and Provides Business Updates Two programs with clinical data readouts in 2H/2025 Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing with preliminary clinical data expected in 2H/2025; Trial now open for enrollment to patients with lupus nephritis (LN) and systemic lupus erythematosus (SLE) Preliminary data for ongoing ADI-270 Phase 1 clinical trial in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) expected in 2H/2025 REDWOOD CITY, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

ACTIVE/129084123.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Adicet Bio Appoints Michael Grissinger to the Board of Directors --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions--

Adicet Bio Appoints Michael Grissinger to the Board of Directors -Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions- REDWOOD CITY, Calif. & BOSTON – April 17, 2025 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoi

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 07, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

As filed with the Securities and Exchange Commission on March 26, 2025

As filed with the Securities and Exchange Commission on March 26, 2025 Registration No.

Up to $100,000,000 Common Stock

Filed pursuant to Rule 424(b)(5) Registration Statement No. 333-285609 PROSPECTUS Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (the Sales Agreement) with Jefferies LLC (Jefferies) relating to shares of our common stock offered by this prospectus. As of the date of this prospectus, the Company has issued no shares of its common stock under the Sales Agreement

Adicet Bio, Inc. 131 Dartmouth Street, Floor 3 Boston, Massachusetts 02116

Adicet Bio, Inc. 131 Dartmouth Street, Floor 3 Boston, Massachusetts 02116 March 12, 2025 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 6, 2025 (File No. 333-285609), as amended Ladies and Gentlemen: Pursua

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) pat

Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress Phase 1 clinical trial of ADI-001 in autoimmune diseases ongoing; on track to report preliminary clinical data from lupus nephritis (LN) patient cohort in 1H25 Additional LN clinical data and preliminary clinical data from other autoimmune patient cohorts anticipated in 2H25 Initiation of

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc.

Description of Securities.

Exhibit 4.1 Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended The summary of the general terms and provisions of the registered securities of Adicet Bio, Inc.(“Adicet,” “we,” or “our”) set forth below does not purport to be complete and is subject to and qualified in its entirety by reference to our Restated Certificate

Form of indenture for senior debt securities and the related form of senior debt security.

Exhibit 4.2 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities ACTIVE/136663340.1 TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ACTIVE/136663340.1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. (

As filed with the Securities and Exchange Commission on March 6, 2025.

As filed with the Securities and Exchange Commission on March 6, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorporation or organization) (I.R.S. Employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adicet Bio, Inc.

Second Amendment to the 2022 Inducement Plan.

Second Amendment to the 2022 Inducement Plan A. The Adicet Bio, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following: “The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,750,000 shares, subject to adjustment as provided in Section 3(c).” B. Th

As filed with the Securities and Exchange Commission on March 6, 2025

As filed with the Securities and Exchange Commission on March 6, 2025 Registration No.

Form of indenture for subordinated debt securities and the related form of subordinated debt security.

Exhibit 4.3 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities ACTIVE/136663339.1 TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ACTIVE/136663339.1 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 05, 2025 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Enrollment underway for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) Company expects

Adicet Bio Announces First Patient Dosed in the Phase 1 Clinical Trial of ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Enrollment underway for patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC) Company expects to share preliminary Phase 1 clinical data in the first half of 2025 REDWOOD CITY, Calif.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrol

Adicet Bio Announces First Lupus Nephritis Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Autoimmune Diseases Enrollment underway for lupus nephritis (LN) patients Preliminary clinical data in LN anticipated in 1H25 Initiation of patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and stiff person syndrome (SPS) expected in 1Q25; patient enrollment in anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) expected in 2H25 REDWOOD CITY, Calif.

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical da

Adicet Opens Enrollment for ADI-270 Phase 1 Clinical Trial in Metastatic/Advanced Clear Cell Renal Cell Carcinoma First gamma delta CAR T cell therapy with the potential to address solid tumors entering clinical trials Preliminary Phase 1 clinical data expected in the first half of 2025 REDWOOD CITY, Calif.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Eighth Amendment to Loan and Security Agreement, by and between Banc of California and Adicet Therapeutics, Inc., dated November 8, 2024.

EIGHTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Eighth Amendment to Loan and Security Agreement (this “Amendment”) is entered into as of November 8, 2024, by and between BANC OF CALIFORNIA, a California state chartered bank (formerly known as Pacific Western Bank) (“Bank”) and ADICET THERAPEUTICS, INC.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

JOINT FILING AGREEMENT

EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Adicet Bio, Inc. and further agree to the filing of this a

ACET / Adicet Bio, Inc. / RTW INVESTMENTS, LP - ADICET BIO, INC. Passive Investment

SC 13G/A 1 p24-3191sc13ga.htm ADICET BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the ap

ACET / Adicet Bio, Inc. / COMMODORE CAPITAL LP Passive Investment

SC 13G/A 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

ACET / Adicet Bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment

SC 13G/A 1 tm2427451d8sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che

Joint Filing Agreement

EX-99.1 2 tm2427451d8ex1.htm EXHIBIT 1 EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of November 14, 2024, is by and among RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (the foregoing are collectively referred to herein as the “Filers”). Each of the Filers may be required to file with the United States Securities and Exchange Commissio

ACET / Adicet Bio, Inc. / TANG CAPITAL MANAGEMENT LLC - AMENDMENT NO. 2 Passive Investment

SC 13G/A 1 acet1015245sc13ga2.htm AMENDMENT NO. 2 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the a

ACET / Adicet Bio, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

SC 13G/A 1 aceta3111224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adicet Bio, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 007002108 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropria

Form of Stock Option Cancellation Agreement.

STOCK OPTION CANCELLATION AGREEMENT This STOCK OPTION CANCELLATION AGREEMENT (the “Agreement”) is made and entered into as of , 2024 (the “Effective Date”), by and between (the “Optionee”) and Adicet Bio, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adice

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 06, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25

Adicet Reports Third Quarter 2024 Financial Results and Provides Business Updates ADI-001 Phase 1 clinical trial expanded to include a total of six autoimmune disease indications; preliminary clinical data in lupus nephritis (LN) anticipated in 1H25 Strong balance sheet with $202.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome ADI-001 clinical development program now addresses six autoimmune diseases Patient enrollment for idiopathic inflamm

Adicet Bio Announces FDA Clearance of IND Amendment to Evaluate ADI-001 in Idiopathic Inflammatory Myopathy and Stiff Person Syndrome ADI-001 clinical development program now addresses six autoimmune diseases Patient enrollment for idiopathic inflammatory myopathy and stiff person syndrome cohort expected to be initiated in the first quarter of 2025 Company plans to report initial clinical data from Phase 1 study in multiple autoimmune diseases in the first half of 2025 REDWOOD CITY, Calif.

ACET / Adicet Bio, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ADICET BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 007002108 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases Activated clinical sites for Phase 1 trial of ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SS

Adicet Opens Enrollment for ADI-001 Phase 1 Clinical Trial in Autoimmune Diseases Activated clinical sites for Phase 1 trial of ADI-001 in autoimmune diseases, including lupus nephritis (LN), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) Enrollment open for patients with LN; enrollment in SLE, SSC, and AAV expected to open in the fourth quarter of 2024 REDWOOD CITY, Calif.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission Fil

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue -Results highlight ADI-001's potential as a best-in-class allogeneic cell therapy for autoimmune disease- -Webcast featur

ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue -Results highlight ADI-001's potential as a best-in-class allogeneic cell therapy for autoimmune disease- -Webcast featuring Dr.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission Fil

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission Fil

Adicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

Adicet Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors REDWOOD CITY, Calif. & BOSTON – August 19, 2024 – Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. “We are ple

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophi

Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates ADI-001 autoimmune clinical development expanded beyond lupus nephritis (LN) to include systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV), following recent U.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 08, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma

Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma Redwood City, Calif.

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumors Phase 1 clinical study to evaluate safety and anti-tumor activ

Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumors Phase 1 clinical study to evaluate safety and anti-tumor activity of ADI-270 in relapsed/ refractory RCC patients Phase 1 clinical study to be initiated in 2H 2024; preliminary clinical data expected in 1H 2025 REDWOOD CITY, Calif.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio, Inc. Restated Certificate of Incorporation

RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC. Adicet Bio, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows: 1. The name of the Corporation is Adicet Bio, Inc. The date of the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware was July 5, 2016 (the “Or

Adicet Bio, Inc. Certificate of Amendment to Third Restated Certificate Amended and Restated Certificate of Incorporation.

CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio, Inc. Certificate of Amendment to Third Restated Certificate Amended and Restated Certificate of Incorporation.

CERTIFICATE OF AMENDMENT OF THIRD AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ADICET BIO, INC.

Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan, as amended.

ADICET BIO, INC. SECOND AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Adicet Bio, Inc. (the “C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 05, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis

Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis Redwood City, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of

Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in 2Q 2024 Strong balance sheet with $247.

ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Candidate Designed for Multiple Solid and Hematological Cancer Indications 27th ASGCT Annual Meeting 2024Baltimore, MD Shon Green, PhD VP, Nonclinical Development

ADI-270: An Armored Allogeneic Anti-CD70 CAR γδ T cell Therapy Candidate Designed for Multiple Solid and Hematological Cancer Indications 27th ASGCT Annual Meeting 2024 Baltimore, MD Shon Green, PhD VP, Nonclinical Development ADI-270: Designed to address multiple refractory cancers CAR utilizes CD27 as the binding domain and contains CD27 and 4-1BB costimulatory domains plus CD3ζ (3rd gen) Inacti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

ACTIVE/129084123.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitt

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 22, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Preclinical findings showed robust anti-tumor activity of ADI-270 in mult

Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models ADI-270 demonstrated enhanced functional potency and resilience in tumor microenvironment On track to file an investigational new drug (IND) application for ADI-270 in 2Q 2024 Preclinical data will be featured in oral presentation on May 10, 2024 REDWOOD CITY, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Open Market Sales AgreementSM, dated as of March 22, 2024, by and between the Company and Jefferies LLC

OPEN MARKET SALE AGREEMENT March 22, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Adicet Bio, Inc.

Up to $100,000,000 Common Stock

PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2022) As Filed Pursuant to Rule 424(b)(5) Registration No.

JOINT FILING AGREEMENT

EX-99.1 2 ss3173481ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 7 to the Schedule 13D, dated March 19, 2024, with respect to the common stock of Adicet Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the u

ACET / Adicet Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 7 Activist Investment

SC 13D/A 1 ss3173481sc13da.htm AMENDMENT NO. 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Adicet Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 007002108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Israel GP Ltd

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. (

Adicet Bio, Inc. Insider Trading Policy.

ADICET BIO, INC. INSIDER TRADING POLICY This memorandum sets forth the policy of Adicet Bio, Inc. and its subsidiaries (collectively, the “Company”) regarding trading in the Company’s securities as described below and the disclosure of information concerning the Company. This Statement of Company Policy on Insider Trading and Disclosure (the “Insider Trading Policy”) is designed to prevent the mis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc.

As filed with the Securities and Exchange Commission on March 19, 2024

As filed with the Securities and Exchange Commission on March 19, 2024 Registration No.

Adicet Bio, Inc. Compensation Recovery Policy.

ADICET BIO, INC. COMPENSATION RECOVERY POLICY Adopted as of November 16, 2023 Adicet Bio, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in acco

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Expanded clinical pipeline into autoimmune diseases with U.S. Food and Drug Administration (FDA) clearance of Investigational New Drug Applicati

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress Expanded clinical pipeline into autoimmune diseases with U.

As filed with the Securities and Exchange Commission on March 19, 2024

As filed with the Securities and Exchange Commission on March 19, 2024 Registration No.

Membership Agreements, dated January 19, 2024 and March 12, 2024, by and between the Registrant and Industrious Bos 131 Dartmouth Street LLC.

Industrious: MEMBERSHIP AGREEMENT Contract Date: January 19, 2024 This Membership Agreement (“Agreement”) is made by and between the Industrious entity or entities (“Industrious”) and the member (“Member”) set forth below: Industrious Member Name INDUSTRIOUS BOS 131 DARTMOUTH STREET LLC Company Name Adicet Bio Location Address 131 Dartmouth Street 3rd Floor Boston, MA 02116 Contact Name Nick Harvey Email nharvey@adicetbio.

ACET / Adicet Bio, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ADICET BIO, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 007002108 (CUSIP Number) FEBRUARY 23, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which t

ACET / Adicet Bio, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment

SC 13G/A 1 o110244sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2023** (Date of Event Which Requires Filing of This Statement) Check the appr

ACET / Adicet Bio, Inc. / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 acet13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

ACET / Adicet Bio, Inc. / RTW INVESTMENTS, LP - ADICET BIO, INC Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to

ACET / Adicet Bio, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Ad

POWER OF ATTORNEY

EX-99.2 Exhibit 2 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick, Erica Herberg, Anat Holt

Joint Filing Agreement

EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of February 5, 2024, is by and among RA Capital Management, L.

ACET / Adicet Bio, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) January 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

ACET / Adicet Bio, Inc. / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

SC 13G/A 1 aceta220224.htm COWEN FINANCIAL PRODUCTS LLC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio Inc. (Name of Issuer) common stock (Title of Class of Securities) 007002108 (CUSIP Number) December 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate

JOINT FILING AGREEMENT

EX-99.1 2 ss2965118ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 6 to the Schedule 13D, dated January 25, 2024, with respect to the common stock of Adicet Bio, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the

ACET / Adicet Bio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 6 Activist Investment

SC 13D/A 1 ss2965118sc13da-adicet.htm AMENDMENT NO. 6 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Adicet Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 007002108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Israel

Adicet Bio, Inc. Announces Proposed Public Offering

Adicet Bio, Inc. Announces Proposed Public Offering REDWOOD CITY, Calif. & BOSTON-Jan. 22, 2024- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stoc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio, Inc. Announces Pricing of Public Offering

Adicet Bio, Inc. Announces Pricing of Public Offering REDWOOD CITY, Calif. and BOSTON, January 22, 2024 – Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the pricing of an underwritten public offering of 27,054,667 shares of its common stock and,

Underwriting Agreement, dated as of January 22, 2024, by and among the Company and Jefferies LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto

27,054,667 Shares And Pre-Funded Warrants to Purchase 8,445,333 Shares Adicet Bio, Inc.

Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 24, 2024).

Form of Pre-Funded Warrant ADICET BIO, INC. WARRANT TO PURCHASE COMMON STOCK Number of Shares: [] (subject to adjustment) Warrant No. [] Original Issue Date: January [], 2024 Adicet Bio, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [] or its registered assigns (the “Holder”) i

27,054,667 Shares of Common Stock Pre-Funded Warrants to Purchase 8,445,333 Shares of Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-263587 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 9, 2022) 27,054,667 Shares of Common Stock Pre-Funded Warrants to Purchase 8,445,333 Shares of Common Stock We are offering 27,054,667 shares of our common stock, par value $0.0001 per share, or the common stock, and, in lieu of common stock to certain investors that so choose, pre-funded wa

Subject to completion, dated January 22, 2024

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

ACET / Adicet Bio, Inc. / COMMODORE CAPITAL LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Agreement dated as of January 19, 2024, by and between Commodore Capital LP and Commodore Capital Master LP (incorporated by reference to Exhibit 1 to the Schedule 13G filed with the Securities and Exchange Commission on January 19, 2024).

Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 16, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer January 16, 2024 γδ= Gamma delta; CAR= Chimeric antigen receptor

Leaders in Developing Allogeneic CAR γδ1 Cell Therapies to Fight Autoimmune Diseases and Cancer January 16, 2024 γδ= Gamma delta; CAR= Chimeric antigen receptor Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2024 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Program Target Potential Indication Discovery Preclinical IND-Enabling Phase 1 Ph 2/3 ADI-001 CD20 NHL ADI-001 CD20 Autoimmune ADI-270 CD70 (TGFβ-DNR) RCC & Other ST / Heme ADI-925* Tumor stress ligands Multiple Solid / Heme ADI-xxx PSMA (w/ Armor) m

Program Target Potential Indication Discovery Preclinical IND-Enabling Phase 1 Ph 2/3 ADI-001 CD20 NHL ADI-001 CD20 Autoimmune ADI-270 CD70 (TGFβ-DNR) RCC & Other ST / Heme ADI-925* Tumor stress ligands Multiple Solid / Heme ADI-xxx PSMA (w/ Armor) mCRPC ADI-002+ GPC3 HCC Adicet Bio Pipeline *ADI-925 is an engineered Chimeric Adapter (CAd) γδ1 T cell product candidate targeting stress ligands, including MICA/MICB & ULBP1-6, expressed on malignant cells.

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical stud

Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024 Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 REDWOOD CITY, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 07, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL) Continuing to enroll mantle cell lymphoma (MCL) patients

Adicet Reports Third Quarter 2023 Financial Results and Provides Business Updates Initiated ADI-001 Phase 1 EXPAND cohort in post chimeric antigen receptor (CAR) T large B cell lymphoma (LBCL) Continuing to enroll mantle cell lymphoma (MCL) patients in ADI-001 Phase 1 study Prioritizing ADI-270 for solid tumor applications; on track to file ADI-270 Investigational New Drug Application (IND) in 1H 2024 REDWOOD CITY, Calif.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adice

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

FOURTH AMENDMENT TO LEASE

Exhibit 10.2 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (the "Agreement") is entered into as of July 31, 2023, 2023 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC., a Delaware corporation ("Tenant"), with respect to the following facts and c

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bio

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates Announced encouraging safety and efficacy data in ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL) On track to report a clinical update for ADI-001 in second half of 2024 Plan to file Investigational New Drug Application (IND) for ADI-925 in H2 2023 and ADI-270 in H1 2024 Strong balance sheet with $205.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc.

Adicet Bio, Inc. Inducement Non-Qualified Stock Option Agreement.

NON-QUALIFIED STOCK OPTION AGREEMENT Adicet Bio, INC. INDUCEMENT NON-QUALIFIED STOCK OPTION AGREEMENT Name of Optionee: Nancy Boman, M.D., Ph.D. No. of Option Shares: 136,000 Option Exercise Price per Share: $18.18 Grant Date: November 30, 2022 Vesting Start Date: November 28, 2022 Expiration Date: November 29, 2032 Adicet Bio, Inc. (the “Company”) hereby grants to the Optionee named above an opti

As filed with the Securities and Exchange Commission on August 9, 2023

As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.

As filed with the Securities and Exchange Commission on August 9, 2023

As filed with the Securities and Exchange Commission on August 9, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Fourth Amendment to Lease, dated as of August 7, 2023, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on August 9, 2023).

Exhibit 10.2 FOURTH AMENDMENT TO LEASE This Fourth Amendment to Lease (the "Agreement") is entered into as of July 31, 2023, 2023 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC., a Delaware corporation ("Tenant"), with respect to the following facts and c

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Announces Appointment of Katie Peng to the Board of Directors

Adicet Announces Appointment of Katie Peng to the Board of Directors REDWOOD CITY, Calif.

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Amendment No.

ACET / Adicet Bio Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 5 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5) Adicet Bio, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 007002108 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP II, L.P. OrbiMed Israel GP Ltd. OrbiMed Israel BioFund GP Limited Partnership

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) ADI-001 demonstrated 71% overall response rate (ORR) and 63% complete response (CR) rate across all dose levels in patients with median 4 prior lines of therapy; 50% of patients enrolled had previously progressed on anti-CD19 chimeric antigen re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 01, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Second Amended and Restated 2018 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 5, 2023).

ADICET BIO, INC. SECOND AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Adicet Bio, Inc. Second Amended and Restated 2018 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Adicet Bio, Inc. (the “C

Sixth Amendment to Loan and Security Agreement, dated as of May 30, 2023, by and between Banc of California, Inc. and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 5, 2023).

SIXTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Sixth Amendment to Loan and Security Agreement (this “Amendment”) is made and entered into as of May 30, 2023, by and between PACIFIC WESTERN BANK, a California state chartered bank (“Bank”), and ADICET THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and dur

Adicet Bio Presents Positive Preclinical Data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting ADI-270 includes Adicet’s proprietary armoring technology and enhancements designed for improved persistence and durability within a solid tumor microenvironment (TME) ADI-270 demonstrated potent anti-tumor activity in CD70+ cancers and improved resilience to clearance from host immune targeting REDWOOD CITY, Calif.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Amended and Restated Non-Employee Director Compensation Policy

ADICET BIO, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Adicet Bio, Inc. (the “Company”), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38359 Adicet Bi

Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet

Adicet Reports First Quarter 2023 Financial Results and Provides Business Updates On track to report additional efficacy, durability and safety data and provide a regulatory update and plan for ADI-001 pivotal program in 2Q 2023 Strong balance sheet with $231.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

As filed with the Securities and Exchange Commission on March 15, 2023

S-8 1 adicet2022s-8.htm S-8 As filed with the Securities and Exchange Commission on March 15, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorporation or o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. (

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc.

Third Amendment to Lease, dated as of January 9, 2023, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord.

THIRD AMENDMENT TO LEASE This Third Amendment to Lease (the "Agreement") is entered into as of January 9, 2023 ("Effective Date"), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC.

First Amendment to the 2022 Inducement Plan (incorporated by reference to Exhibit 10.23 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2023).

First Amendment to the 2022 Inducement Plan A. The Adicet Bio, Inc. 2022 Inducement Plan (the “2022 Inducement Plan”) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following: “The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 2,000,000 shares, subject to adjustment as provided in Section 3(c).” B. The

First Amendment to Antibody Discovery Agreement, dated as of November 8, 2022, by and between the Registrant and Twist Bioscience Corporation (incorporated by reference to Exhibit 10.11 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2023).

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”.

Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress

Adicet Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Company Progress • Announced interim safety and efficacy data for ADI-001 in ongoing Phase 1 study for the potential treatment of relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL); Next data update expected in Q2 2023 • Announced preclinical data for differentiated chimeric antigen receptor (CAR) and chimeric adaptor (CAd) programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting and Adicet’s R&D Pipeline Event REDWOOD CITY, Calif.

ACET / Adicet Bio Inc / TANG CAPITAL PARTNERS LP Passive Investment

Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.0001 par value per share, of Adicet Bio, Inc. and further agree to the filing of this agreement as an exhibit thereto. I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

ACET / Adicet Bio Inc / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d994088913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate

ACET / Adicet Bio Inc / RTW INVESTMENTS, LP - ADICET BIO, INC. Passive Investment

SC 13G/A 1 p23-0488sc13ga.htm ADICET BIO, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2022 (Date of event which requires filing of this statement) Check the app

ACET / Adicet Bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* ADICET BIO, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 007002108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul

ACET / Adicet Bio Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Adicet Bio Inc. (Name of Issuer) common stock (Title of Class of Securities) 007002108 (CUSIP Number) December 30, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul

ACET / Adicet Bio Inc / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) December 12, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all

Adicet Bio Reports Positive Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) ADI-001 demonstrated 75% overall response rate (ORR) and 69% complete response (CR) across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high-grade aggressive NHL, as of December 5, 2022 data

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Fifth Amendment to Loan and Security Agreement, dated as of December 2, 2022, between Adicet Therapeutics, Inc. and Banc of California, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on December 8, 2022).

FIFTH AMENDMENT TO LOAN AND SECURITY AGREEMENT This Fifth Amendment to Loan and Security Agreement (this ?Amendment?) is entered into as of December 2, 2022, by and between PACIFIC WESTERN BANK, a California state chartered bank (?Bank?) and ADICET THERAPEUTICS, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 02, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Virtual R&D Event November 10, 2022

Virtual R&D Event November 10, 2022 Forward-Looking Statements This presentation contains "forward-looking statements" of Adicet Bio, Inc.

Up to $100,000,000 Common Stock

As Filed Pursuant to Rule 424(b)(5) Registration No. 333-254193 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 30, 2021) Up to $100,000,000 Common Stock We entered into a Capital On Demand™ Sales Agreement, dated March 12, 2021, or the Sales Agreement, with JonesTrading Institutional Services LLC, or JonesTrading, pursuant to which we may offer and sell shares of our common stock, par value $0.0

Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study du

Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates As of ASH abstract data-cut date, ADI-001 demonstrated a positive safety and efficacy profile; Company to provide more recent data cut from its ongoing Phase 1 study during ASH Annual Meeting Company to host ADI-001 webcast event on December 11, 2022 at 9:00 a.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bi

Antibody Discovery Agreement, dated as of March 23, 2021, by and between the Registrant and Twist Bioscience Corporation (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on November 8, 2022).

EXHIBIT 10.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH ?[***]?. SUCH IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. TWIST BIOSCIENCE ANTIBODY DISCOVERY AGREEMENT This Antibody Discovery Agreement (?Agreement?) is entered into as

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 08, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 03, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) As of the July 15, 2022 ASH abstract data-cut date, ADI-001 demonstrated a 78% overall and complete respo

Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL) As of the July 15, 2022 ASH abstract data-cut date, ADI-001 demonstrated a 78% overall and complete response rate and sustained durability in patients, including those previously exposed to CAR T therapy 100% ORR and CR rate in four anti-CD19 CAR T relapsed patients ADI-001 continued to demonstrate a favorable safety and tolerability profile Clinical data will be presented during poster presentation at ASH Annual Meeting on Saturday, December 10, 2022, from 5:30 – 7:30 p.

ACET / Adicet Bio Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ADICET BIO, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 007002108 (CUSIP Number) October 5, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 05, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio, Inc. Pipeline chart as of October 5, 2022.

Exhibit 99.1

POWER OF ATTORNEY

Exhibit 2 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings.

ACET / Adicet Bio Inc / Carlyle Group Inc. - SC 13D/A Activist Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 007002108 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Address and

JOINT FILING AGREEMENT

Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D.

Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressi

Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive NHL, as of May 31, 2022 data-cut date ADI-001 received FDA Fast Track Designation Strong balance sheet with $304.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, In

Second Amendment to Lease, dated as of June 16, 2022, between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC, as Landlord (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 21, 2022).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File N

Second Amendment to Lease, dated as of June 16, 2022, between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC, as Landlord (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on June 21, 2022).

Exhibit 10.1 SECOND AMENDMENT TO LEASE (EXPANSION) This Second Amendment to Lease (the "Agreement") is entered into as of June 16, 2022 (?Effective Date?), by and between WESTPORT OFFICE PARK, LLC, a Delaware limited liability company (formerly a California limited liability company) ("Landlord"), and ADICET THERAPEUTICS, INC., a Delaware corporation ("Tenant"), with respect to the following facts

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 06, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with re

Exhibit 99.1 Adicet Bio Reports Emerging Data from ADI-001 Phase 1 Trial at the American Society of Clinical Oncology Annual Meeting ADI-001 demonstrated 75% CR and ORR rate across all dose levels with favorable safety and tolerability profile in patients with relapsed/refractory high grade aggressive Non-Hodgkin?s Lymphoma (NHL), as of May 31, 2022 data-cut date 80% ORR and CR rate at dose levels

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 02, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Num

Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL) As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive prelim

Exhibit 99.1 Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin?s Lymphoma (NHL) As of the February 14, 2022 ASCO abstract data-cut date, ADI-001 demonstrated a 67% complete response rate with positive preliminary durability data and a favorable safety and tolerability profile Updated data from a May 31, 2022 data-cut date will be presented du

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, I

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.9million in cash and cash equivalents

Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates Interim data from ADI-001 Phase 1 trial accepted for oral presentation at 2022 ASCO Annual Meeting Strong balance sheet with $277.

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 05, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Numb

Adicet Bio, Inc. 200 Clarendon Street, Floor 6 Boston, Massachusetts 02116

Adicet Bio, Inc. 200 Clarendon Street, Floor 6 Boston, Massachusetts 02116 May 5, 2022 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Adicet Bio, Inc.: Registration Statement on Form S-3, filed March 15, 2022 (File No. 333-263587), as amended Ladies and Gentlemen: Pursuant to Rule 461 under the S

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies Non-gene-edited ADI

Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies ADI-001 exhibited robust in vitro and in vivo tumor growth inhibition in multiple human lymphoma cell lines, with adaptive and innate mechanisms contributing to its anti-tumor activity Non-gene-edited ADI-001 gamma delta CAR T cells demonstrated superior resilience to host versus graft targeting when compared to common gene-edited approaches MENLO PARK, Calif.

ACET / Adicet Bio Inc / Cowen Financial Products LLC - COWEN FINANCIAL PRODUCTS LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Adicet Bio Inc. (Name of Issuer) common stock (Title of Class of Securities) 007002108 (CUSIP Number) April 01, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001

Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001 Menlo Park, CA and Boston, MA ? April 19, 2022 ? Adicet Bio, Inc.

Change Order No. 3, dated March 18, 2022, by and between Adicet Therapeutics, Inc. and CP Enterprises, Inc. d/b/a CP Construction (incorporated by reference to Exhibit 10.3 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on March 24, 2022).

ocument G701 Change Order Change Order Number: 03 Project: Adicet Therapeutics 1000 Bridge Parkway Redwood City, CA 94065 Architect's Project No: Owner Architect ? ? To Contractor: (Name and Address CP Construction a Division of CP Enterprises Newark, CA 94560 Contract For: Tenant Improvements Contractor Field Other ? ? ? The Contract is changed as follows: (Include, where applicable, any undisputed amount attributable to previously executed Construction Change Directives) Pressurized Change Adicet GxP Lab Rev 01 (Per Pricing Revision 02 set & the 1/20/22 Preliminary Schedule) Demo $ 165,000.

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Change Order No. 1, dated September 23, 2021, by and between Adicet Therapeutics, Inc. and CP Enterprises, Inc. d/b/a CP Construction (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on March 24, 2022).

Document G701 Change Order Change Order Number: 01 Project: Adicet Therapeutics 1000 Bridge Parkway Redwood City, CA 94065 Date: 21-Sep-21 Architect's Project No: Owner Architect ? ? To Contractor: (Name and Address CP Construction a Division of CP Enterprises Newark, CA 94560 Contract Date: 2 April 2021 Contract For: Tenant Improvements Contractor Field Other ? ? ? The Contract is changed as follows: (Include, where applicable, any undisputed amount attributable to previously executed Construction Change Directives) Pressurized Change Per Western Allied and Adicet email dated 8/23/21 for the following work: Demolition of Installed Duet Upsizing (4) Evs Upsize exhaust duct runs Upsize supply duct run Upsize (9) grilles Subtotal $ 124,000.

Change Order No. 2, dated March 18, 2022, by and between Adicet Therapeutics, Inc. and CP Enterprises, Inc. d/b/a CP Construction (incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on March 24, 2022).

Document G701 Change Order Change Order Number: 02 Project: Adicet Therapeutics 1000 Bridge Parkway Redwood City, CA 94065 Date: 7-Feb-22 Architect's Project No: Owner Architect ? ? To Contractor: (Name and Address CP Construction a Division of CP Enterprises Newark, CA 94560 Contract Date: 2 April 2021 Contract For: Tenant Improvements Contractor Field Other ? ? ? The Contract is changed as follows: (Include, where applicable, any undisputed amount attributable to previously executed Construction Change Directives) Vivarium Modifications Per email correspondence with Charlie Penner on 2/3/22 for the following work: Demo $ 2,500.

As filed with the Securities and Exchange Commission on March 15, 2022

As filed with the Securities and Exchange Commission on March 15, 2022 Registration No.

As filed with the Securities and Exchange Commission on March 16, 2022.

As filed with the Securities and Exchange Commission on March 16, 2022. Registration No. 333-263587 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 PRE-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorp

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Adicet Bio, Inc.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2022 Adicet Bio, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File Nu

Amended and Restated 2018 Stock Option and Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.11 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed on March 15, 2022).

Exhibit 10.11 ADICET BIO, INC. AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan (the ?Plan?). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Adicet Bio, Inc. (the ?C

Form of indenture for subordinated debt securities and the related form of subordinated debt security.

Exhibit 4.4 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Subordinated Debt Securities ACTIVE/107686520.2 TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ACTIVE/107686520.2 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2

Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.17 to the Registrant’s Annual Report on Form 10-K filed with the SEC on March 15, 2022).

Exhibit 10.17 ADICET BIO, INC. FORM OF DIRECTOR INDEMNIFICATION AGREEMENT This Indemnification Agreement (?Agreement?) is made as of [] by and between Adicet Bio, Inc., a Delaware corporation (the ?Company?), and [Director] (?Indemnitee?). RECITALS WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company; WHEREAS, in

Amended and Restated Senior Executive Cash Incentive Bonus Plan (incorporated by reference to Exhibit 10.19 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).

Exhibit 10.19 ADICET BIO, INC. AMENDED AND RESTATED SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN 1. Purpose This Senior Executive Cash Incentive Bonus Plan (the ?Incentive Plan?) is intended to provide an incentive for superior work and to motivate eligible executives of Adicet Bio, Inc. (the ?Company?) and its subsidiaries toward even higher achievement and business results, to tie their goals and

Amended and Restated 2018 Employee Stock Purchase Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.14 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed on March 15, 2022).

Exhibit 10.14 ADICET BIO, INC. AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN The purpose of the Adicet Bio, Inc. Amended and Restated 2018 Employee Stock Purchase Plan (?the Plan?) is to provide eligible employees of Adicet Bio, Inc. (the ?Company?) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company?s common stock, par value $0.0

2022 Inducement Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).

Exhibit 10.15 ADICET BIO, INC. 2022 INDUCEMENT PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Adicet Bio, Inc. 2022 Inducement Plan (the ?Plan?). The purpose of the Plan is to encourage and enable Adicet Bio, Inc. (the ?Company?) to grant equity awards to induce highly-qualified prospective officers and employees to accept employment and provide them with a pr

Form of Employment Agreement (incorporated by reference to Exhibit 10.16 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 15, 2022).

Exhibit 10.16 EMPLOYMENT AGREEMENT This Employment Agreement (?Agreement?) is made between Adicet Bio, Inc., a Delaware corporation (the ?Company?), and (the ?Executive?). WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on (the ?Effective Date?) on the terms contained herein. NOW, THEREFORE, in consideration of the mutual coven

Filing Fee Table

EX-FILING FEES 6 acet-exfilingfees64.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Adicet Bio, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Agg

Amended and Restated Non-Employee Director Compensation Policy.

Exhibit 10.18 ADICET BIO, INC. AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the ?Policy?) of Adicet Bio, Inc. (the ?Company?), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-38359 Adicet Bio, Inc. (

Form of indenture for senior debt securities and the related form of senior debt security.

Exhibit 4.3 ADICET BIO, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [?], 202[?] Senior Debt Securities ACTIVE/107686489.2 TABLE OF CONTENTS1 1 This Table of Contents does not constitute part of the Indenture and shall not have any bearing on the interpretation of any of its terms or provisions. ACTIVE/107686489.2 ARTICLE 1 DEFINITIONS Section 1.01 Definitions of Terms ARTICLE 2 ISSUE

As filed with the Securities and Exchange Commission on March 15, 2022.

As filed with the Securities and Exchange Commission on March 15, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 81-3305277 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ

Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

Exhibit 99.1 Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress ? Complete and near complete responses observed starting at lowest dose in interim findings from Phase 1 study of ADI-001 in non-Hodgkin?s lymphoma (NHL); additional interim clinical data expected in the first half of 2022 ? Successfully raised $94.2 million in net proceeds throug

Specimen stock certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.3 to the Registrant’s Annual Report on Form 10-K (File No. 001-38359) filed on March 15, 2022).

Exhibit 4.3 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate Number ZQ00000000 Adicet Bio Shares **000000 ****************** ***000000 ***************** **** 000000 **************** ***** 000000 *************** ****** 000000 ************** Adicet Bio, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alex

ACET / Adicet Bio Inc / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2022 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Joint Filing Statement Pursuant to Rule 13d-1(k)(1)

EX-1 2 ex1.htm Exhibit 1 Joint Filing Statement Pursuant to Rule 13d-1(k)(1) The undersigned hereby consent and agree to the joint filing of Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Common Stock, par value $0.0001 per share of Adicet Bio, Inc. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties

US76133L1035 / resTORbio, Inc. / RTW INVESTMENTS, LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Adicet Bio, Inc.

FORM OF LOCK-UP AGREEMENT

EX-99.2 3 ss678938ex9902.htm FORM OF LOCK-UP AGREEMENT FORM OF LOCK-UP AGREEMENT December 5, 2021 Jefferies LLC Guggenheim Securities, LLC As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 RE: Adicet Bio, Inc. (the “Company”) Ladies & Gentlemen: The undersigned is a

JOINT FILING AGREEMENT

EX-99.1 2 ss678938ex9901.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this amendment to Schedule 13D, dated December 14, 2021 (the “Schedule 13D”), with respect to the Shares of Adicet Bio, Inc. is filed, and all amendments thereto will be filed, on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1

US76133L1035 / resTORbio, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 4 Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Adicet Bio, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 76133L103 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Advisors Israel II Limited OrbiMed Israel GP Ltd. OrbiMed Israel GP II, L.P. OrbiMed Israel Bi

Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock

EX-99.2 5 acet-ex992.htm EX-99.2 Exhibit 99.2 Adicet Bio, Inc. Announces Pricing of Public Offering of Common Stock MENLO PARK, Calif. and BOSTON, December 8, 2021 (GLOBE NEWSWIRE) – Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta CAR T cell therapies for cancer and other diseases, today announced the pricing of an underwritten

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2021 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File

Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock

EX-99.1 4 acet-ex991.htm EX-99.1 Exhibit 99.1 Adicet Bio, Inc. Announces Proposed Follow-On Offering of Common Stock MENLO PARK, Calif. and BOSTON, Mass., December 7, 2021 (GLOBE NEWSWIRE) – Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, today announced that it has commenced an un

Underwriting Agreement, dated as of December 7, 2021, by and among the Company and Jefferies, LLC and Guggenheim Securities, LLC, as representatives of the several underwriters listed on Schedule A thereto

Exhibit 1.1 6,250,000 Shares Adicet Bio, Inc. UNDERWRITING AGREEMENT December 7, 2021 JEFFERIES LLC GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters named in Schedule A attached hereto c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Introductory. Adicet Bio, Inc.,

6,250,000 Shares Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-254193 PROSPECTUS SUPPLEMENT (To Prospectus dated March 30, 2021) 6,250,000 Shares Common Stock We are offering shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?ACET.? On December 3, 2021, the last reported sale price of our common stock was $9.80 per share. Investing in our common stock invol

$ Common Stock

The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 Adicet Bio, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38359 81-3305277 (State or Other Jurisdiction of Incorporation) (Commission File